LLY — ELI LILLY & Co
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 59478 ·
Last close
$1157.08
Market Cap
$1.03T
52W High
$1292.65
52W Low
$758.52
ADV30
2,436,583
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 22,974,000,000 | 19,706,000,000 | 12,457,000,000 | 7,095,000,000 | 142,283,000,000 | 8,950,000,000 | 108,404,000,000 |
| Mar 2026 | 19,799,000,000 | 16,222,000,000 | 9,778,000,000 | 7,396,000,000 | 116,576,000,000 | 5,282,000,000 | 85,378,000,000 |
| Dec 2025 | 19,292,000,000 | 15,920,300,000 | 8,987,400,000 | 6,637,700,000 | 112,476,000,000 | 7,268,000,000 | 85,941,000,000 |
| Sep 2025 | 17,600,800,000 | 14,592,500,000 | 8,386,100,000 | 5,582,500,000 | 114,935,400,000 | 9,791,900,000 | 91,084,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$20,480,000,000
Investing CF
$-11,535,000,000
Financing CF
$-7,063,000,000
CapEx
$-10,112,000,000
Dividends Paid
$-5,586,000,000
Buybacks
$-5,264,000,000
EPS Diluted TTM
$28.15
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$29,514,000,000
Inventory
$14,529,000,000
Receivables
$21,177,000,000
ST Investments
$121,600,000
EBIT TTM
$35,774,200,000
Pretax Income TTM
$31,125,000,000
Interest Exp TTM
$897,000,000
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$79,666,003,968
EBITDA
$41,706,999,808
Free Cash Flow
$11,065,900,032
Enterprise Value
$1,040,445,079,552
Total Cash
$8,949,999,616
Total Debt
$54,907,998,208
Shares Out
891,741,406
Trailing EPS
$29.79
Book Value
$38.00
ROE
102.3%
ROA
20.4%
Div Yield
0.62%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 65,179,000,000 | 29,696,000,000 | 20,640,000,000 | 112,476,000,000 | 85,941,000,000 | 26,535,000,000 | 16,813,000,000 |
| Dec 2024 | 45,043,000,000 | 17,040,000,000 | 10,590,000,000 | 78,715,000,000 | 64,443,000,000 | 14,272,000,000 | 8,818,000,000 |
| Dec 2023 | 34,124,000,000 | 10,325,000,000 | 5,240,000,000 | 64,006,300,000 | 53,142,600,000 | 10,771,900,000 | 4,240,000,000 |
| Dec 2022 | 28,541,400,000 | 8,280,400,000 | 6,244,800,000 | 49,489,800,000 | 38,714,400,000 | 10,649,800,000 | 7,585,700,000 |
TTM Snapshot
Revenues TTM
$40,608,300,000
NetIncome TTM
$5,123,600,000
OpCashFlow TTM
$0
Assets (Latest)
$112,476,000,000
Forward EPS
$47.24
Max Pain — expiry 2026-10-09 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1180.00 · spot: $1157.08 · call volume: 3,224 · put volume: 2,438
Expected Move to 2026-10-09:
±$62.15
(5.37%) —
implied range
$1094.93 –
$1219.23
· ATM straddle on $1157.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | $638.00B | $264.74 | — |
| ABBV | AbbVie Inc. | $462.26B | $261.59 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
| NVSEF | NOVARTIS AG | $267.87B | $140.93 | — |
News headlines (Yahoo Finance, 1h cache)
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
2026-09-30 22:00 · Yahoo
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3
2026-09-30 20:43 · Yahoo
Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug
2026-09-30 20:09 · Yahoo
Eli Lilly (LLY) Stock Stays Undervalued As Its 437% Run Raises Stakes
2026-09-30 20:09 · Yahoo
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
2026-09-30 18:51 · Yahoo
Sector Update: Healthcare Stocks Softer Wednesday Afternoon
2026-09-30 17:40 · Yahoo
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
2026-09-30 17:34 · Yahoo
2 Outstanding Dividend Stocks to Buy and Hold for a Decade
2026-09-30 17:20 · Yahoo
Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.
2026-09-30 16:24 · Yahoo
Eli Lilly stock rises on striking 23% weight loss in drug combo trial
2026-09-30 14:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.